EP0700255A4 - Composition de dextrose monohydratee et de glucose - Google Patents
Composition de dextrose monohydratee et de glucoseInfo
- Publication number
- EP0700255A4 EP0700255A4 EP94913846A EP94913846A EP0700255A4 EP 0700255 A4 EP0700255 A4 EP 0700255A4 EP 94913846 A EP94913846 A EP 94913846A EP 94913846 A EP94913846 A EP 94913846A EP 0700255 A4 EP0700255 A4 EP 0700255A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- weight
- composition
- homeopathic
- potency
- titration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 21
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 title claims abstract description 14
- 239000008121 dextrose Substances 0.000 title claims abstract description 11
- 150000004682 monohydrates Chemical class 0.000 title claims abstract description 11
- 239000008103 glucose Substances 0.000 title claims abstract description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 18
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims abstract description 14
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 14
- 230000001632 homeopathic effect Effects 0.000 claims abstract description 9
- 238000004448 titration Methods 0.000 claims abstract description 9
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 7
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 7
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 7
- 239000011787 zinc oxide Substances 0.000 claims abstract description 7
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 6
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 6
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 6
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 6
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 6
- 159000000003 magnesium salts Chemical class 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 4
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims abstract description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 6
- 239000000395 magnesium oxide Substances 0.000 claims description 3
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 3
- 235000011009 potassium phosphates Nutrition 0.000 claims description 3
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 206010019133 Hangover Diseases 0.000 abstract description 3
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000011777 magnesium Substances 0.000 description 7
- 229910052749 magnesium Inorganic materials 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 6
- 159000000001 potassium salts Chemical class 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000026473 slurred speech Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/60—Sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a composition for the treatment of a "hangover" i.e. the after-effects of excessive consumption of ethyl alcohol by a human being.
- An object of the invention is the provision of a composition which can be taken as a single treatment (in one or more doses) to counteract a hangover.
- the present invention provides a composition including:- a major proportion of monohydrate dextrose or glucose in combination with the following compounds:
- liver activity As the liver increases its normal rate of breaking down glycogen into blood sugar, to restore the optimum blood sugar level.
- Continual or frequent such increase in liver activity can lead to cirrhosis of the liver.
- the brain uses about 25% of available blood sugar, and so is particularly rapidly effected by a drop in blood sugar levels:- hence the symptoms of slurred speech, memory lapses, headaches, loss of co-ordination, blurred vision, personality changes, and so on commonly associated with alcohol consumption.
- Monohydrate dextrose breaks down to glucose in the body, and thus both monohydrate dextrose and glucose are quickly and readily assimilated into the blood stream to boost the blood sugar level and help prevent liver damage and counteract brain disfunction.
- magnesium and potassium salts are magnesium sulphate, magnesium oxide, and potassium phosphate.
- magnesium and potassium salts may be used.
- magnesium and potassium salts and vitamin C are much more readily and easily absorbed into the system if taken into the system with monohydrate dextrose or glucose:- the monohydrate dextrose or glucose effectively coats said other constituents and prevents them from being destroyed by stomach acids, and also speeds their circulation around the system.
- Zinc oxide assists the pancreas with the production of insulin, and hence facilitates the absorption of glucose into the blood.
- Zinc oxide also is known to be effective in detoxifying the system i.e. combatting the after-effects of alcohol.
- vitamin B6 in the composition considerably increases the rate of activity of the composition and thus gives more rapid relief to a user. It appears that vitamin B6 and magnesium salts are synergistic i.e. the presence of one increases the effectiveness of the other, and thus reduces the amount of each needed in the composition to achieve the desired effect.
- the constituents of the composition act to raise the user's blood sugar level and replenish lost vitamin C, magnesium and potassium, and also interact with each other to mutually increase their effectiveness and to speed their assimilation into the system.
- composition also may contain one or more of the following:
- a preferred embodiment of the present composition comprises:
- the composition is in the form of a powder, and is taken dissolved in water or in tablet form. It has been found that the composition is more effective if the user lies on the right side after taking the composition, because this allows the composition to pass more quickly though the duodenum into the intestine, for absorption into the system.
- the composition may be prepared in liquid form, and drunk or given by injection.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Composition pour le traitement de la 'gueule de bois' consistant en une majeure partie de dextrose monohydratée ou de glucose combinée aux constituants suivants: 0,5% à 2% en poids d'acide ascorbique; un sel non toxique de potassium à dilution 6C dans la classification homéopathique, ou jusqu'à 0,4% en poids; un sel non toxique de magnésium à dilution 6C dans la classification homéopathique, ou jusqu'à 0,4% en poids; de 0,0001% à 2,5% en poids de vitamine B6; de l'oxyde de zinc à dilution 6C dans la classification homéopathique, ou jusqu'à 0,07% en poids.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ24770193 | 1993-05-26 | ||
| NZ24770193 | 1993-05-26 | ||
| PCT/NZ1994/000042 WO1994027449A1 (fr) | 1993-05-26 | 1994-05-10 | Composition de dextrose monohydratee et de glucose |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0700255A1 EP0700255A1 (fr) | 1996-03-13 |
| EP0700255A4 true EP0700255A4 (fr) | 1997-02-26 |
Family
ID=19924357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP94913846A Withdrawn EP0700255A4 (fr) | 1993-05-26 | 1994-05-10 | Composition de dextrose monohydratee et de glucose |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0700255A4 (fr) |
| CN (1) | CN1124444A (fr) |
| AU (1) | AU676314B2 (fr) |
| CA (1) | CA2162877C (fr) |
| WO (1) | WO1994027449A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9601398D0 (en) * | 1996-01-24 | 1996-03-27 | Piper Edwina M | Composition |
| FR2748936A1 (fr) * | 1996-05-23 | 1997-11-28 | Clergeaud Jean | Solution buvable favorisant la baisse du taux d'alcoolemie |
| FR2748904A1 (fr) * | 1996-05-27 | 1997-11-28 | Turpin Veronique | Complement nutritionnel personnalise a base de sels biochimiques de schuessler |
| WO1999026492A1 (fr) * | 1997-11-21 | 1999-06-03 | Turpin Veronique | Complement nutritionnel a base de sels biochimiques de schuessler |
| KR100309715B1 (ko) * | 1998-04-07 | 2001-12-28 | 이명희 | 구연산회로를활성화시켜알코홀독성과숙취를예방하는기능을가지는조성물 |
| KR100828708B1 (ko) * | 2007-06-19 | 2008-05-09 | 씨제이제일제당 (주) | 숙취의 예방 또는 치료용 조성물 |
| KR101498780B1 (ko) * | 2013-04-18 | 2015-03-04 | 씨제이제일제당 (주) | 숙취의 예방 또는 치료용 조성물 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH370631A (de) * | 1957-05-03 | 1963-07-15 | Heinrich Dr Vogler | Verfahren zur Herstellung eines als Zusatz zu Nahrungsmitteln und Getränken bestimmten Präparates |
| EP0482715A1 (fr) * | 1990-10-26 | 1992-04-29 | Maurizio Luca | Composition nutritionnelle |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0087068A1 (fr) * | 1982-02-12 | 1983-08-31 | Thomas Moses Dr. Beck | Supplément d'aliments |
| NL8403433A (nl) * | 1984-11-09 | 1986-06-02 | Holland Melkunie | Voedingssuppletiepreparaat op basis van melkbestanddelen. |
| US5108767A (en) * | 1991-06-10 | 1992-04-28 | Abbott Laboratories | Liquid nutritional product for persons receiving renal dialysis |
-
1994
- 1994-05-10 EP EP94913846A patent/EP0700255A4/fr not_active Withdrawn
- 1994-05-10 WO PCT/NZ1994/000042 patent/WO1994027449A1/fr not_active Application Discontinuation
- 1994-05-10 CN CN94192255A patent/CN1124444A/zh active Pending
- 1994-05-10 CA CA002162877A patent/CA2162877C/fr not_active Expired - Fee Related
- 1994-05-10 AU AU65844/94A patent/AU676314B2/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH370631A (de) * | 1957-05-03 | 1963-07-15 | Heinrich Dr Vogler | Verfahren zur Herstellung eines als Zusatz zu Nahrungsmitteln und Getränken bestimmten Präparates |
| EP0482715A1 (fr) * | 1990-10-26 | 1992-04-29 | Maurizio Luca | Composition nutritionnelle |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO9427449A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2162877C (fr) | 2004-04-13 |
| EP0700255A1 (fr) | 1996-03-13 |
| WO1994027449A1 (fr) | 1994-12-08 |
| AU6584494A (en) | 1994-12-20 |
| AU676314B2 (en) | 1997-03-06 |
| CA2162877A1 (fr) | 1994-12-08 |
| CN1124444A (zh) | 1996-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5053396A (en) | Therapeutic composition | |
| EP0669083B1 (fr) | Boisson contenant de la créatine; procédé de préparation | |
| Rastogi et al. | Selenium and lead: mutual detoxifying effects | |
| US6740502B2 (en) | Method for preparing zinc-oligopeptide easily absorbable by the human body | |
| EP0271489B1 (fr) | Composition therapeutique | |
| US7498039B2 (en) | Nutritional supplement containing sea water minerals | |
| CA2162877C (fr) | Composition a base de dextrose ou de glucose monohydrate | |
| EP1340504A1 (fr) | Medicament contre le diabete | |
| KR100613618B1 (ko) | 운동에 동반하여 일어나는 산화적 대사를 지속시키는 방법 및스포츠용 음식물 | |
| DE68903147T2 (de) | Zusammensetzungen und verfahren zum erlangen einer verbesserten physiologischen reaktion bei leibesuebungen. | |
| US5639482A (en) | Composition for control and prevention of diabetic retinopathy | |
| JP2533709B2 (ja) | 体力増強剤 | |
| NZ265404A (en) | Composition for treatment of hangover | |
| JP2970957B2 (ja) | 精製花粉栄養調整物 | |
| US5348749A (en) | Method for treating panic disorder | |
| JP3241173B2 (ja) | 入浴剤 | |
| KR20120110955A (ko) | 타우린, 이노시톨, 비타민ｃ, 비타민 ｂ군 및 요오드화칼륨을 주성분으로 함유하는 기능성 음료조성물 | |
| JP3793239B2 (ja) | アセトアルデヒド毒性の抑制剤 | |
| JP2007314560A (ja) | 運動に伴って起こる酸化的代謝を持続させる剤 | |
| US4474801A (en) | α-Amino-γ-butyrolactones for treating alcohol dependence | |
| JP2002080376A (ja) | 生物活性剤および医薬 | |
| KR20120119686A (ko) | Ｌ-아르기닌, 비타민ｃ, 비타민 ｂ군, 비타민ａ, 비타민ｅ 및 요오드화칼륨을 주성분으로 함유하는 기능성 음료조성물 | |
| US3055805A (en) | Process of treating acidosis with t.h.a.m. | |
| RU2146529C1 (ru) | Набор антиалкогольных средств | |
| Van Harreveld et al. | The dual effect of L-proline on spreading depression in the chicken retina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19951204 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
| RAX | Requested extension states of the european patent have changed |
Free format text: SI PAYMENT 951204 |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 19970107 |
|
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
| 18W | Application withdrawn |
Withdrawal date: 19990329 |